# FDA 483 - Mark Adaimy MD - November 16, 2020

Source: https://www.globalkeysolutions.net/records/483/mark-adaimy-md/83bf6a60-7d2d-41d6-b791-472ec9babcdc

> FDA 483 for Mark Adaimy MD on November 16, 2020. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Mark Adaimy MD
- Inspection Date: 2020-11-16
- Product Type: drugs
- Office Name: Division of Human and Animal Food Operations - West V
- Summary: An FDA inspection of Mark J. Adalmy, MD, Clinical Investigator in Las Vegas, NV, revealed significant non-compliance with clinical investigation protocols. The firm failed to properly report serious adverse events, administered incorrect or expired doses, and neglected required laboratory safety assessments for study subjects. These findings indicate a serious lack of adherence to regulatory requirements and study protocols.

## Related Officers

- [investigator](https://www.globalkeysolutions.net/people/rebecca-t-davis/a821f7ef-0c73-4be1-9a9b-3fc2c07f88c1)

Company: https://www.globalkeysolutions.net/companies/mark-adaimy-md/2ca93f28-1df0-4d7b-839d-c2bcda8e9ccd

Office: https://www.globalkeysolutions.net/offices/division-of-human-and-animal-food-operations-west-v/0f4dd01e-8e8a-4336-9abe-ce8b3d309e8b